Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
about
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersPsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Treatment of psychosis and dementia in Parkinson's disease.Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in ratsReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report.Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literatureThe relationships between mild cognitive impairment and phenotype in Parkinson's diseaseEffects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Behavioral effects of levodopa.Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Parkinson's psychosis.Behavioral disturbances in Parkinson's diseasePharmacologic management of psychosis in the elderly: a critical review.Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.Psychotic symptoms in Parkinson's disease: pathophysiology and management.Psychosis in Parkinson's disease.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Treatment of behavioural symptoms and dementia in Parkinson's disease.Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case reportA review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies.Intervening in the neuropsychiatric features of Parkinson's disease.Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report.New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Mild cognitive impairment in Parkinson's disease: the challenge and the promiseDiagnosis and management of Parkinson's disease dementia.Atypical antipsychotic drugs in the treatment of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson's disease patients with visual hallucinations.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Neuropsychiatric Issues in Parkinson's Disease.The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease.Late (Complicated) Parkinson's Disease
P2860
Q24605472-BFD9D088-A8B7-42E1-BDA9-210A6E8A857DQ30249553-54268916-6328-4CCB-A7F6-4DB611E172C3Q30358337-5DDF289A-5205-46F6-AD92-00E4FDFB2311Q30497096-1DC4D780-A91E-44C2-AF3C-C7A16D64F5F9Q33260251-91288331-86FB-410F-BDEC-743A0D77699FQ33686420-0C0C8503-5FB7-4B8F-A536-7667258289F4Q33686426-DB0FA732-886E-47CD-B6B5-03C5D2DFE8BAQ33917203-A8CD69CD-311D-41A6-82B4-DC0A94FAA6EAQ34032505-0C50383C-2961-4E00-9D29-3479BFE81CF3Q34452922-6B4B2B7A-861C-41FD-BBD6-A9919793021EQ34610608-6E8E2993-FB35-4A40-94B2-AB46EBC5F23FQ34610632-262525AA-14F7-4867-A27C-3AC0C706E041Q35236819-C979306C-A443-4B56-8BF3-656E07E0F073Q35599469-527E200C-3017-4A20-9600-89DDF9A125AAQ35687749-1A01A731-54E0-4555-83CE-92199E6C3678Q35779329-4E84004A-007D-4E28-83FC-E47C0582DD96Q35863404-07CB83EF-1E5A-4F54-968D-6AE27AFA3171Q35863422-E75BF715-30FD-4BE5-8C8A-7B781C2EC7D3Q36089350-1C4A8136-2D08-4809-A8D5-4C6FDE82CC79Q36092585-BC7ABE58-D3BF-4D02-8C8E-35CCB60A2168Q36118555-1CBE50BA-B166-4704-A986-1D5DCEC24195Q36425995-F3CD4756-C0A3-4CE2-9A8D-B40A59275C81Q36806669-2FEE544F-8CD2-4D7E-81A1-3B5E99D5E89BQ36847266-FAF8C00B-9403-45E1-9D0A-2D0ED0291D16Q36932291-AA017AF8-F650-425F-8575-0C49BD2405D3Q37021326-CD700EA0-AE70-478F-940A-77A0C57D2CD9Q37196144-9F1CAF3B-FA76-4DCD-8C16-B3C62B3B9F27Q37281128-46B71980-7800-4BF1-B955-CF1584617E5BQ37957772-9554FB21-6FCE-4E83-996C-C3CDAF6ACB0AQ38070888-2A9D87F8-0330-4B43-A018-A57B3988681EQ38132755-545D8DC1-B005-437C-9A78-761BA6143442Q38588201-97765B34-74C9-45B6-94E9-C5B7D3F1DB10Q38634752-E136DF24-61D7-4DBC-9C75-09C96FCC64AEQ38661735-85E83DBB-730B-4FDE-BC1D-E00F429357B3Q38662579-F3F9E5CD-6EF6-46C7-9271-A99C87E25544Q38799051-A552B24A-4D9B-4D50-A98F-697CE2463386Q43164212-24B89208-EC78-4779-88F2-3A74828CF633Q48529264-6B9EE9DE-A443-4912-9A45-0475F83B3212Q58870320-D9A0CD85-1233-4FD2-999F-F81DBDF8CA8B
P2860
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Rivastigmine for the treatment ...... nson's disease: a case series.
@en
Rivastigmine for the treatment ...... nson's disease: a case series.
@nl
type
label
Rivastigmine for the treatment ...... nson's disease: a case series.
@en
Rivastigmine for the treatment ...... nson's disease: a case series.
@nl
prefLabel
Rivastigmine for the treatment ...... nson's disease: a case series.
@en
Rivastigmine for the treatment ...... nson's disease: a case series.
@nl
P1476
Rivastigmine for the treatment ...... nson's disease: a case series.
@en
P2093
P304
P356
10.1185/030079902125000813
P407
P577
2002-01-01T00:00:00Z